miRecule™ is an early-stage biotechnology company developing microRNA-based therapeutics. Two of the major problems in cancer therapy are accurately classifying patients based on how their unique cancer will respond to a given drug, and treating patients whose cancer initially responds to a drug, but then returns in a drug-resistant form. Our goal at miRecule™ is to create therapeutic drugs that address these two critical issues simultaneously, through a genomic based drug development platform.